基本信息
浏览量:94
职业迁徙
个人简介
Dr. Johnson’s research interests involve understanding the biology of lung cancer and improving the treatment of this and other solid tumors. He played a role in the development of the new targeted drugs bevacizumab (Avastin) and erlotinib (Tarceva) both of which are now FDA-approved for the treatment of lung cancer.
研究兴趣
论文共 755 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Vito Filbert Jayalie,David Johnson,Sudibio Sudibio, Rudiyo Rudiyo, Juli Jamnasi, Hendriyo Hendriyo, Jose Roel Resubal, Dan Joseph Manlapaz, Marjorie Cua, Janell Marie Genson, Cesar Vincent Villafuerte III, Jennifer Alzaga,
Journal of Medicine, University of Santo Tomasno. 1 (2024): 1381-1389
The Biochemical journalno. 22 (2023): 1805-1816
crossref(2023)
Feng Zhu,Martijn E.T. Dollé, Thomas R. Berton,Raoul V. Kuiper, Carrie Capps,Alexsandra Espejo,Mark J. McArthur,Mark T. Bedford,Harry van Steeg,Annemieke de Vries,David G. Johnson
crossref(2023)
Feng Zhu,Martijn E.T. Dollé, Thomas R. Berton,Raoul V. Kuiper, Carrie Capps,Alexsandra Espejo,Mark J. McArthur,Mark T. Bedford,Harry van Steeg,Annemieke de Vries,David G. Johnson
crossref(2023)
Youen Jiang,David Johnson
arXiv (Cornell University) (2023)
Hong Jiang,Vanesa Martin,Candelaria Gomez-Manzano,David G. Johnson,Marta Alonso, Erin White,Jing Xu, Timothy J. McDonnell,Naoki Shinojima,Juan Fueyo
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn